Details

Autor(en) / Beteiligte

• Mackay, Alexander J
• Kostikas, Konstantinos
• Roche, Nicolas
• Frent, Stefan-Marian
• Olsson, Petter
• Pfister, Pascal
• Gupta, Pritam
• Patalano, Francesco
• Banerji, Donald
• Wedzicha, Jadwiga A

Titel

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study

Ist Teil von

• Respiratory research, 2020-04, Vol.21 (1), p.93-93, Article 93

Ort / Verlag

England: BioMed Central

Erscheinungsjahr

2020

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• COPD is a heterogeneous disease and patients may respond differently to therapies depending on baseline symptom burden. This post-hoc analysis from the 52-week FLAME study investigated the impact of baseline symptom burden in terms of health status, dyspnoea, bronchitis status, eosinophil levels and smoking status on the subsequent risk of moderate or severe exacerbations. Health status was measured by St. George's Respiratory Questionnaire (SGRQ) score (higher ≥46.6 and lower < 46.6) and COPD Assessment Test (CAT) score (higher ≥17 and lower < 17); dyspnoea and bronchitis were assessed via an electronic diary (eDiary). Differential response to once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg versus twice-daily salmeterol/fluticasone (SFC) 50/500 μg was assessed. Data from 3354 patients was analysed. The risk of exacerbations was lower in patients who had less severe health impairment (rate ratio [RR] [95% CI]): SGRQ-C, (0.88 [0.78, 0.99]); CAT, 0.85 [0.75, 0.96]) and lower dyspnoea (0.79 [0.69, 0.90]) at baseline versus those with more severe health impairment and higher dyspnoea, respectively. Compared with SFC, IND/GLY led to better prevention of moderate-to-severe exacerbations in the majority of groups studied. Patients with more severe health status impairment and greater symptom burden at baseline subsequently experienced more exacerbations in the FLAME study. IND/GLY was overall more effective in preventing exacerbations versus SFC, regardless of baseline symptom burden. Our results suggest that future studies on novel exacerbation therapies should consider targeting patients with higher symptom burden at baseline. NCT01782326.